GSK plc
GSK
$46.66
-$0.45-0.95%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.52B | 10.67B | 9.47B | 10.40B | 10.43B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.52B | 10.67B | 9.47B | 10.40B | 10.43B |
| Cost of Revenue | 3.01B | 2.88B | 2.42B | 3.25B | 3.02B |
| Gross Profit | 8.51B | 7.78B | 7.04B | 7.15B | 7.40B |
| SG&A Expenses | 2.91B | 2.80B | 2.59B | 3.36B | 2.69B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -280.47M | -328.61M | -226.71M | 153.68M | -218.62M |
| Total Operating Expenses | 7.77B | 7.41B | 6.55B | 9.12B | 7.37B |
| Operating Income | 3.76B | 3.26B | 2.91B | 1.28B | 3.05B |
| Income Before Tax | 3.31B | 2.52B | 2.65B | 721.01M | 83.28M |
| Income Tax Expenses | 420.70M | 321.94M | 423.18M | 79.40M | -1.30M |
| Earnings from Continuing Operations | 2.89B | 2.20B | 2.23B | 641.61M | 84.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -176.64M | -271.17M | -186.40M | -111.42M | -160.06M |
| Net Income | 2.71B | 1.93B | 2.05B | 530.19M | -75.48M |
| EBIT | 3.76B | 3.26B | 2.91B | 1.28B | 3.05B |
| EBITDA | 4.75B | 4.80B | 3.95B | 1.96B | 4.29B |
| EPS Basic | 0.67 | 0.47 | 0.50 | 0.13 | -0.02 |
| Normalized Basic EPS | 0.51 | 0.41 | 0.38 | 0.14 | 0.41 |
| EPS Diluted | 0.66 | 0.47 | 0.50 | 0.13 | -0.02 |
| Normalized Diluted EPS | 0.50 | 0.40 | 0.38 | 0.14 | 0.40 |
| Average Basic Shares Outstanding | 4.03B | 4.06B | 4.09B | 4.08B | 4.08B |
| Average Diluted Shares Outstanding | 4.10B | 4.11B | 4.14B | 4.15B | 4.14B |
| Dividend Per Share | 0.22 | 0.21 | 0.20 | 0.20 | 0.20 |
| Payout Ratio | 32.29% | 45.46% | 37.68% | 147.83% | -1,055.17% |